Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Lung Cancer Specialty Channel

Lung Cancer
Specialty Channel
News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
Deborah Doroshow, MD, PhD
Videos
09/23/2023

Featuring Deborah Doroshow, MD, PhD 

Featuring Deborah Doroshow, MD, PhD  ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates...
09/23/2023
Oncology
News
07/20/2023
Allison Casey
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology
News
07/10/2023

Stephanie Holland

Stephanie Holland
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show...
07/10/2023
Oncology
News
07/10/2023

Amber Denham

Amber Denham
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell...
07/10/2023
Oncology
News
02/22/2023

Derek Cowsert

Derek Cowsert
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off...
02/22/2023
Oncology
News
02/22/2023

Derek Cowsert

Derek Cowsert
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in...
02/22/2023
Oncology
News
02/16/2023

Derek Cowsert

Derek Cowsert
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor...
02/16/2023
Oncology
News
02/07/2023

Derek Cowsert

Derek Cowsert
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal...
02/07/2023
Oncology
News
02/07/2023

Derek Cowsert

Derek Cowsert
A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.
A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.
A study found old age to be a...
02/07/2023
Oncology

Advertisement

News

News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
Deborah Doroshow, MD, PhD
Videos
09/23/2023

Featuring Deborah Doroshow, MD, PhD 

Featuring Deborah Doroshow, MD, PhD  ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates...
09/23/2023
Oncology
News
07/20/2023
Allison Casey
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology
News
07/10/2023

Stephanie Holland

Stephanie Holland
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show...
07/10/2023
Oncology
News
07/10/2023

Amber Denham

Amber Denham
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell...
07/10/2023
Oncology
News
02/22/2023

Derek Cowsert

Derek Cowsert
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off...
02/22/2023
Oncology
News
02/22/2023

Derek Cowsert

Derek Cowsert
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in...
02/22/2023
Oncology
News
02/16/2023

Derek Cowsert

Derek Cowsert
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor...
02/16/2023
Oncology
News
02/07/2023

Derek Cowsert

Derek Cowsert
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal...
02/07/2023
Oncology

Interactive Features

Quiz
09/08/2022
What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?
What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?
What did the phase 2 CITYSCAPE...
09/08/2022
Oncology
Quiz
09/08/2022
According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?
According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?
According a phase 2 study, what...
09/08/2022
Oncology
elderly screening patient
Quiz
03/15/2022
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting,...
03/15/2022
Oncology
Test Your Knowledge
12/09/2021
True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.
True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.
True or false: According to...
12/09/2021
Oncology
Quiz
08/15/2021
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to...
08/15/2021
Oncology
Test Your Knowledge
08/09/2021
True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.
True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.
True or false: Pembrolizumab in...
08/09/2021
Oncology
Test Your Knowledge
08/06/2021
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib...
08/06/2021
Oncology
Test Your Knowledge
08/03/2021
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of...
08/03/2021
Oncology
Test Your Knowledge
07/06/2021
Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?
Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?
Which treatment showed efficacy...
07/06/2021
Oncology
Test Your Knowledge
03/23/2021
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
Which of the following...
03/23/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement